Summary
In this article the role of functional imaging (PET and SPECT) as a surrogate marker for following the progression of Parkinson’s disease (PD) is discussed. The potential value of PET and SPECT for assessing the efficacy of putative neuroprotective agents in PD is considered and a review of 18F-dopa PET findings in transplantation trials involving implantation of human and procine fetal mesencephalic tissue is presented. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective and restorative approaches to PD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Alexander T, Sortwell CE, Sladek CD, Roth RH, Steece-Collier K (1997) Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fischer 344 and Sprague-Dawley donors. Cell Transplant 6: 309-315
Banati RB, Goerres GW, Brooks DJ et al (1999a) PK11195 positron emission tomography imaging of activated microglia in Rasmussen’s encephalitis. Neurology 53: 2199-2203
Banati R, Cagnin A, Myers R et al (1999b) In vivo detection of activated microglia by ["C]PK11195-PET indicates involvement of the globus pallidum in idiopathic Parkinson’s disease. Parkinsonism Relat Disord 5: S56 (abstr)
Brundin P, Pogarel O, Hagell P et al (2000) Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease. Brain (in press)
Ellias SA, Palmer EP, Kott HS et al (1998) Transplantation of fetal porcine ventral mesencephalic cells for treatment of Parkinson’s disease: One year safety and efficacy results. Neurology 50 Suppl 4: A80
Fahn S, Elton RL, and members of the UPDRS development committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M et al (eds) Recent developments in Parkinson’s disease. Macmillan, New York, 153-163
Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain 114: 2283-2301
Freed CR, Breeze RE, Rosenberg NL et al (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N Engl J Med 327: 1549-1555
Freeman TB, Olanow CW, Hauser RA et al (1995) Bilateral fetal nigral transplantion into the post-commisural putamen as a treatment for Parkinson’s disease: six months follow-up. Ann Neurol 38: 379-388
Hagell P, Schrag AE, Piccini P et al (1999) Sequential bilateral transplantation in Parkinson’s disease: Effects of the second graft. Brain 122: 1121-1132
Hauser RA, Freeman TB, Snow BJ et al (1999) Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56: 179-187
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992a) The accuracy of the clinical diagnosis of Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992b) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: A clinicopathological study. Neurology 42: 1142-1146
Jellinger K (1987) The pathology of parkinsonism. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, 33-65
Kordower JH, Freeman TB, Snow BJ et al (1995) Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 332: 1118-1124
Kordower JH, Freeman TB, Chen EY et al (1998) Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. Mov Disord 13: 383-393
Kuwabara H, Cumming P, Reith J et al (1993) Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[’8F]fluorodopa and positron emission tomography: Error analysis and application to normal subjects. J Cereb Blood Flow Metab 13: 43-56
Lang AE, Benabid AL, Koller WC et al (1995) The Core Assessment Program for intracerebral transplantation. Mov Disord 10: 527-528
Langston JW, Widner H, Goetz CG et al (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7: 2-13
Leber P (1997) Slowing the progression of Alzheimer disease: Methodologic issues. Alzheimer Dis Assoc Disord 11 Suppl 5: S10-S20
Louis DE, Tang MX, Cote L, Alfaro B, Mejia H, Marder KM (1999) Progression of parkinsonian signs in Parkinson’s disease. Arch Neurol 56: 334-337
Marek KL, Innis RB, Seibyl J (1998) Assessment of Parkinson’s disease progression with 3-CIT and SPECT imaging. Mov Disord 13 Suppl 2: 238 (abstr)
Martinez-Martin P, Gil-Nagel A, Gracia LM et al (1994) Unified Parkinson’s disease rating scale: characteristics and structure. Mov Disord 9: 76-83
Morrish PK, Sawle GV, Brooks DJ (1995) Clinical and [18F]dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry 59: 597-600
Morrish PK, Sawle GV, Brooks DJ (1996) An [18F]dopa PET and clinical study of the rate of progression in Parkinson’s disease. Brain 119: 585-591
Morrish PK, Rakshi JS, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64: 314-319
Nurmi EM, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Rinne JO (1999) The rate of progression in Parkinson’s disease: A [18F]Dopa PET study. Neurology 52 Suppl 2: A91 (abstr)
Olanow CW, Jenner P, Brooks D (1998) Dopamine agonists and neuroprotection in Parkinson’s disease. Ann Neurol 44 Suppl 1: S167-S174
Otsuka M, Ichiya Y, Kuwabara Y et al (1996) Differences in the reduced 18F-dopa uptakes of the caudate and the putamen in Parkinson’s disease: Correlations with the three main symptoms. J Neurol Sci 136: 169-173
Pate BD, Kawamata T, Yamada T et al (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34: 331-338
Piccini P, Brooks DJ, Bjorklund A et al (1999) Dopamine release from nigral transplants visualised in vivo in a Parkinson’s patient. Nat Neurosci 2: 1137-1140
Rakshi JS, Bailey DL, Morrish PK, Brooks DJ (1996) Implementation of 3D acquisition, reconstruction, and analysis of dynamic [18F] Fluorodopa studies. In: Myers R, Cunningham V, Bailey D, Jones T (eds), Quantification of brain function using PET. Academic Press, San Diego, 82-87
Remy P, Samson Y, Hantraye P et al (1995) Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 38: 580-588
Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS (1990) Striatal function in normal aging: Implications for Parkinson’s disease. Ann Neurol 28: 799-804.
Shoulson I, The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364-1371
Snow BJ, Tooyama I, McGeer EG et al (1993) Human positron emission tomographic I18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34: 324-330
Turjanski N, Lees AJ, Brooks DJ (1999) Striatal dopaminergic receptor dysfunction in patients with restless legs syndrome: 18F-dopa and "C-raclopride PET studies. Neurology 52: 932-937
Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36: 759-764
Ward CD (1994) Does selegiline delay the progression of Parkinson’s disease? A critical reevaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 57: 217-220
Widner H, Tetrud J, Rehncrona S et al (1992) Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP). N Engl J Med 327: 1556-1563
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Wien
About this paper
Cite this paper
Brooks, D.J. (2000). Monitoring neuroprotection and restorative therapies in Parkinson’s disease with PET. In: Riederer, P., et al. Advances in Research on Neurodegeneration. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6301-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6301-6_8
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83537-1
Online ISBN: 978-3-7091-6301-6
eBook Packages: Springer Book Archive